Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation


Posted: 2021-09-14 19:00:00
. 2021 Sep 14. doi: 10.14348/molcells.2021.076. Online ahead of print. Affiliations Expand Affiliations 1 Laboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Jeonbuk National University, Iksan 54531, Korea. 2 Ilsong Institute of Life Science, Hallym University, Seoul 07247, Korea. 3 Korea Zoonosis Research Institute, Jeonbuk National University, Iksan 54531, Korea. 4 College of Veterinary Medicine, Jeonbuk National University, Iksan 54531, Korea. Item in Clipboard Yun-Sook Lim et al. Mol Cells. 2021. Show details Display options Display options Format . 2021 Sep 14. doi: 10.14348/molcells.2021.076. Online ahead of print. Affiliations 1 Laboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Jeonbuk National University, Iksan 54531, Korea. 2 Ilsong Institute of Life Science, Hallym University, Seoul 07247, Korea. 3 Korea Zoonosis Research Institute, Jeonbuk National University, Iksan 54531, Korea. 4 College of Veterinary Medicine, Jeonbuk National University, Iksan 54531, Korea. Item in Clipboard CiteDisplay options Display options Format Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has become a global health concern. Various SARS-CoV-2 vaccines have been developed and are being used for vaccination worldwide. However, no therapeutic agents against coronavirus disease 2019 (COVID-19) have been developed so far; therefore, new therapeutic agents are urgently needed. In the present study, we evaluated several hepatitis C virus direct-acting antivirals as potential candidates for drug repurposing against COVID-19. Theses include asunaprevir (a protease inhibitor), daclatasvir (an NS5A inhibitor), and sofosbuvir (an RNA polymerase inhibitor). We found that asunaprevir, but not sofosbuvir and daclatasvir, markedly inhibited SARS-CoV-2-induced cytopathic effects in Vero E6 cells. Both RNA and protein levels of SARS-CoV-2 were significantly decreased by treatment with asunaprevir. Moreover, asunaprevir profoundly decreased virion release from SARS-CoV-2-infected cells. A pseudoparticle entry assay revealed that asunaprevir blocked SARS-CoV-2 infection at the binding step of the viral life cycle. Furthermore, asunaprevir inhibited SARS-CoV-2 propagation in human lung Calu-3 cells. Collectively, we found that asunaprevir displays broad-spectrum antiviral activity and therefore might be worth developing as a new drug repurposing candidate for COVID-19. Keywords: COVID-19; SARS-CoV-2; asunaprevir; drug repurposing; hepatitis C virus.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
4月 07, 2021 バイオアソシエイツ

超音波はコロナウイルスに損傷を与える可能性があることをMITのシミュレーションが示唆

コロナウイルスは、いばらの冠に似た密集した表面受容体を備えた構造をしている。 これらのスパイク状タンパク質は健康な細胞をしっかり掴み、ウイルスRNAの侵入を引き起こす。 ウイルスの形状と感染戦略は一般的に理解されているが、その物理的完全性についてはほとんど知られていない。MITの機械工学科の研究者による新研究は、コロナウイルスが医用画像診断で使用される周波数内で超音波振動に対して脆弱である可能性があることを示唆している。…